Prediction: Oracle Stock Could Hit This Price by 2027

Oracle shares are down 33% in 2026, but the article argues the selloff is overdone given a large $638B backlog (RPO vs. $67.4B FY26 revenue). Management expects to convert 12% of RPO into revenue in the next year and 34% over 13–36 months, supporting a 33% jump in FY27 revenue to $90B. Despite debt rising to $167.4B (up $43B last year) and plans to raise another $40B in FY27, analysts forecast EPS growth from +5.4% in FY27 to +36% in FY28 and an 85% upside to a $243 median 12-month target (with potential price reaching $328 under higher valuation assumptions).

Analysis

The market is treating this as a financing quality issue, not a demand issue. That matters because the equity only wins if the incremental capital is converted into revenue faster than the cost of debt and dilution; otherwise the balance sheet becomes the real bottleneck even with a large backlog. In that frame, ORCL behaves less like a software compounder and more like a levered infrastructure owner, so the multiple can stay compressed until the company proves free-cash-flow conversion is outrunning financing drag.

Second-order winners are the picks-and-shovels beneficiaries of the same capex cycle, especially NVDA and data-center power equipment vendors, because they get paid on the buildout immediately while Oracle absorbs execution and financing risk. The less obvious loser is any AI cloud competitor with weaker access to capital; Oracle’s willingness to lever up can force a more expensive capacity race and pressure pricing discipline across the sector. Over 1-3 months, the catalyst is not the backlog headline but the next financing package and whether credit spreads remain benign.

The contrarian miss is that a backlog is not a margin bridge. The consensus appears to be assuming RPO conversion automatically turns into higher equity value, but if interest expense and dilution rise faster than operating leverage, the stock can underperform even in a strong revenue year. Six to eighteen months out, the key falsifier is any sign that revenue growth is accelerating while per-share earnings and FCF per share fail to keep pace; that would imply the market was right to discount the story.

Key Decisions for Investors

• Relative-value: long NVDA / short ORCL for 1-3 months to express AI infrastructure demand while avoiding Oracle’s financing and dilution overhang; thesis breaks if ORCL announces materially better-than-expected funding terms or NVDA demand cools.
• Do not chase ORCL here; wait for the next debt/equity package to price and for credit spreads to stay contained before adding. If Oracle’s borrowings widen meaningfully or equity issuance is larger than planned, treat that as a sell-the-rally signal rather than a buy signal.
• Watchlist alert on ORCL for a post-financing pullback: if the stock de-risks after issuance but management reiterates conversion rates and FCF guidance, the setup improves for a 6-18 month long. The falsifier is any guidance reset on revenue-to-cash conversion.
• Use NVDA as the cleaner expression of the capex cycle rather than a levered ORCL bet; if the AI buildout remains intact, NVDA captures the spending now while ORCL still has to prove return on capital.